PT3557254T - Domínios de ligação de proteína estabilização de estados conformacionais funcionais de gpcrs e usos do mesmo - Google Patents

Domínios de ligação de proteína estabilização de estados conformacionais funcionais de gpcrs e usos do mesmo

Info

Publication number
PT3557254T
PT3557254T PT191690049T PT19169004T PT3557254T PT 3557254 T PT3557254 T PT 3557254T PT 191690049 T PT191690049 T PT 191690049T PT 19169004 T PT19169004 T PT 19169004T PT 3557254 T PT3557254 T PT 3557254T
Authority
PT
Portugal
Prior art keywords
gpcrs
binding domains
protein binding
conformational states
functional conformational
Prior art date
Application number
PT191690049T
Other languages
English (en)
Original Assignee
Univ Brussel Vrije
Vib Vzw
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brussel Vrije, Vib Vzw, Univ Leland Stanford Junior filed Critical Univ Brussel Vrije
Publication of PT3557254T publication Critical patent/PT3557254T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
PT191690049T 2010-07-16 2011-07-18 Domínios de ligação de proteína estabilização de estados conformacionais funcionais de gpcrs e usos do mesmo PT3557254T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39978110P 2010-07-16 2010-07-16
GBGB1014715.5A GB201014715D0 (en) 2010-09-06 2010-09-06 Nanobodies stabilizing functional conformational states of GPCRS

Publications (1)

Publication Number Publication Date
PT3557254T true PT3557254T (pt) 2022-01-20

Family

ID=43037319

Family Applications (5)

Application Number Title Priority Date Filing Date
PT191690049T PT3557254T (pt) 2010-07-16 2011-07-18 Domínios de ligação de proteína estabilização de estados conformacionais funcionais de gpcrs e usos do mesmo
PT231859976T PT4273549T (pt) 2010-07-16 2011-07-18 Domínios de ligação às proteínas que estabilizam os estados conformacionais funcionais dos gpcrs e seus usos
PT191690056T PT3557255T (pt) 2010-07-16 2011-07-18 Domínios de ligação de proteína estabilização de estados conformacionais funcionais de gpcrs e usos do mesmo
PT117340786T PT2593792T (pt) 2010-07-16 2011-07-18 Domínios de ligação de proteína estabilizadores de estados conformacionais funcionais e usos da gpcr
PT117324988T PT2593791T (pt) 2010-07-16 2011-07-18 Domínios de ligação a proteína que estabilizam estados conformacionais funcionais de gpcrs e as suas utilizações

Family Applications After (4)

Application Number Title Priority Date Filing Date
PT231859976T PT4273549T (pt) 2010-07-16 2011-07-18 Domínios de ligação às proteínas que estabilizam os estados conformacionais funcionais dos gpcrs e seus usos
PT191690056T PT3557255T (pt) 2010-07-16 2011-07-18 Domínios de ligação de proteína estabilização de estados conformacionais funcionais de gpcrs e usos do mesmo
PT117340786T PT2593792T (pt) 2010-07-16 2011-07-18 Domínios de ligação de proteína estabilizadores de estados conformacionais funcionais e usos da gpcr
PT117324988T PT2593791T (pt) 2010-07-16 2011-07-18 Domínios de ligação a proteína que estabilizam estados conformacionais funcionais de gpcrs e as suas utilizações

Country Status (15)

Country Link
US (16) US20130137856A1 (pt)
EP (7) EP3557255B1 (pt)
JP (4) JP6302248B2 (pt)
CN (1) CN103180734B (pt)
BR (1) BR112013001180B1 (pt)
CA (1) CA2805560C (pt)
DK (5) DK2593791T3 (pt)
ES (5) ES2907049T3 (pt)
FI (1) FI4273549T3 (pt)
GB (1) GB201014715D0 (pt)
HR (3) HRP20220326T1 (pt)
HU (2) HUE070205T2 (pt)
PL (5) PL3557255T3 (pt)
PT (5) PT3557254T (pt)
WO (2) WO2012007593A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP3345919A1 (en) 2011-06-21 2018-07-11 VIB vzw Binding domains directed against gpcr:g protein complexes and uses derived thereof
ES2656972T3 (es) 2012-02-23 2018-03-01 Vanderbilt University Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4
CN103509115B (zh) * 2012-06-21 2016-03-23 中国科学院上海生命科学研究院 人胱抑素c纳米抗体及其应用
EP2867674B1 (en) 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
DK2951201T3 (en) * 2013-01-30 2018-01-08 Vib Vzw Novel chimeric polypeptides for screening and drug detection purposes
AU2014214054B2 (en) * 2013-02-05 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Muscarinic acetylcholine receptor binding agents and uses thereof
WO2014124020A1 (en) * 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner
WO2014153044A1 (en) * 2013-03-14 2014-09-25 Temple University Of The Commonwealth System Of Higher Education Treatment of patients with hyponatremia and cardiac disease
RU2678421C2 (ru) 2013-06-28 2019-01-28 Экс-Боди, Инк. Обнаружение антигена-мишени, фенотипический скрининг и его применение для идентификации специфичных эпитопов-мишеней клеток-мишеней
EP3036233A1 (en) 2013-08-23 2016-06-29 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN103454413B (zh) * 2013-09-04 2015-03-11 吉日木图 双峰驼特异性抗体制备及免疫检测方法
CA2924879C (en) * 2013-09-23 2023-01-10 X-Body, Inc. Methods and compositions for generation of binding agents against cell surface antigens
DK3194976T3 (da) 2014-07-22 2020-07-13 Vib Vzw Fremgangsmåder til udvælgelse af midler, som stabiliserer proteinkomplekser
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
DE102016116391B3 (de) * 2016-09-01 2018-02-01 Gea Mechanical Equipment Gmbh Verfahren zum Überwachen einer Schneckenzentrifuge
US11668021B2 (en) 2017-05-09 2023-06-06 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
CA3063334A1 (en) 2017-05-12 2019-12-05 Riken Modified class a gpcr binding compound
CN107423555B (zh) * 2017-06-09 2020-06-30 王�忠 一种探索药物新适应症的方法
WO2019032661A1 (en) * 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
CN109553687B (zh) * 2017-09-27 2021-07-06 北京大学 基于g蛋白偶联受体构建的荧光探针
CA3076250A1 (en) * 2017-10-02 2019-04-11 Vib Vzw Compounds to inhibit bacterial s-layer protein assembly
KR20250070615A (ko) 2017-10-31 2025-05-20 브이아이비 브이지더블유 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도
KR102485253B1 (ko) * 2017-11-10 2023-01-06 현대자동차주식회사 대화 시스템 및 그 제어방법
BR112021000100A2 (pt) * 2018-07-05 2021-03-30 Novobind Livestock Therapeutics Inc. Anticorpos contra agentes causadores de doença de aves domésticas e usos dos mesmos
CN110759998A (zh) * 2018-07-27 2020-02-07 深圳康体生命科技有限公司 一种gfp抗体制备方法及其dna序列
CN114041056A (zh) 2019-04-29 2022-02-11 康福治疗有限公司 用于跨膜蛋白尤其是gpcr的筛选方法和测定
KR20220034034A (ko) * 2019-05-01 2022-03-17 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 면역센서
WO2020226907A1 (en) * 2019-05-07 2020-11-12 Beijing Neoletix Biological Technology Co., Ltd. Fusion protein of single domain antibody and procoagulant
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
BR112022016555A2 (pt) 2020-02-21 2022-11-16 Origimm Biotechnology Gmbh Tratamento profilático e imunoterapêutico para propionibacterium acnes
CN115884988A (zh) * 2020-05-28 2023-03-31 小利兰·斯坦福大学托管委员会 防止封闭和半封闭空间中病毒和微生物污染的雾化粘液抑制纳米抗体
EP4217000A4 (en) * 2020-09-25 2024-10-30 The Board of Trustees of the Leland Stanford Junior University POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY
CN112843222B (zh) * 2021-01-21 2023-01-31 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
CN112851811B (zh) * 2021-01-28 2022-08-09 姜国胜 一种cd44v6纳米抗体及其作为白血病研究试剂的应用
US12282027B2 (en) 2021-02-19 2025-04-22 University Of South Florida High-throughput NMR approach for in-membrane protein ligand screening
WO2022258437A1 (en) * 2021-06-07 2022-12-15 Paul Scherrer Institut Quantification of protein-protein interaction of membrane proteins using high-mass mass spectrometry
CN113717874B (zh) * 2021-09-27 2023-04-11 四川大学 一种耐高温、耐高糖的酿酒酵母菌株及其构建方法和应用
IL315386A (en) * 2022-03-04 2024-11-01 Coagulant Therapeutics Corp Camel antibodies against active protein C and uses thereof
WO2023201173A2 (en) * 2022-04-11 2023-10-19 Vanderbilt University Anti-cox-2 nanobodies for endoscopic visualization of colorectal adenomas
WO2024192704A1 (en) * 2023-03-22 2024-09-26 Biofront Therapeutics (Beijing) Co., Ltd. Nanobodies that bind to gprc5d and uses thereof
CN116813781B (zh) * 2023-07-29 2024-01-12 十堰市太和医院（湖北医药学院附属医院） 一种靶向β2AR的纳米抗体及其制备方法和应用
WO2025100417A1 (ja) * 2023-11-06 2025-05-15 株式会社ダイセル Ａａｖのフルカプシドに対するアフィニティポリペプチド
CN118324905B (zh) * 2024-06-14 2024-09-03 广州明药科技有限公司 抗人β2微球蛋白的纳米抗体及其应用
CN118894930A (zh) * 2024-07-31 2024-11-05 演生潮(北京)生物科技有限公司 一种基于生物学活性评价的纳米抗体快速筛查方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2937474B2 (ja) * 1988-10-03 1999-08-23 スクリップス クリニック アンド リサーチ ファウンデーション レセプター誘導結合部位に対するモノクローナル抗体
EP0437547B1 (en) 1988-10-03 1999-12-29 The Scripps Research Institute Monoclonal antibodies against receptor-induced binding sites on ligands binding to proteins of the cytoadhesin super family
ATE452207T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US20020192711A1 (en) * 2001-04-20 2002-12-19 Nestor John J. Methods for identifying ligands of G-Protein-Coupled receptors
US20030129649A1 (en) 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
WO2004035614A1 (en) * 2001-07-11 2004-04-29 Karo Bio Ab Synthetic or partially purified peptides which can bind to specific subunits of g proteins and uses thereof
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US9029097B2 (en) 2005-02-16 2015-05-12 Universite De Montreal Biosensors for monitoring receptor-mediated G-protein activation
WO2006108183A2 (en) * 2005-04-05 2006-10-12 Corning Incorporated Label free biosensors and cells
AU2006301426A1 (en) * 2005-10-11 2007-04-19 Ablynx N.V. NanobodiesTM and polypeptides against EGFR and IGF-IR
KR20080102408A (ko) * 2006-02-22 2008-11-25 필로겐 에스.피.에이. 혈관 종양 마커
EP2557090A3 (en) * 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
JP4842400B2 (ja) 2007-03-22 2011-12-21 ヘプテアズ・セラピューティクス・リミテッド Ｇタンパク質共役型受容体変異体及びその選択方法
JP5425056B2 (ja) * 2007-05-15 2014-02-26 エフ．ホフマン−ラ ロシュ アーゲー Ｇタンパク質共役受容体（ｇｐｃｒ）に対する抗体
US7947807B2 (en) * 2007-10-15 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3)
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
NZ589036A (en) * 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
DK2285408T3 (en) * 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
WO2010030182A2 (en) * 2008-09-10 2010-03-18 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
DK2367840T3 (en) 2008-12-08 2015-10-12 Complix N V SINGLE CHAIN ​​antiparallel coiled-coil PROTEINS
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP3345919A1 (en) 2011-06-21 2018-07-11 VIB vzw Binding domains directed against gpcr:g protein complexes and uses derived thereof
AU2014214054B2 (en) 2013-02-05 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Muscarinic acetylcholine receptor binding agents and uses thereof
EP3099707B1 (en) 2014-01-30 2021-12-29 Vib Vzw Opioid receptor binding agents and uses thereof

Also Published As

Publication number Publication date
US20130137856A1 (en) 2013-05-30
DK3557254T3 (da) 2022-01-24
EP4273549B1 (en) 2024-11-06
AU2011278244B2 (en) 2016-01-28
AU2011278244B8 (en) 2016-02-11
US10436796B2 (en) 2019-10-08
US20160347842A1 (en) 2016-12-01
JP7248637B2 (ja) 2023-03-29
US10054598B2 (en) 2018-08-21
HUE070205T2 (hu) 2025-05-28
ES2907049T3 (es) 2022-04-21
US9863959B2 (en) 2018-01-09
PL2593791T3 (pl) 2017-08-31
US20220099683A1 (en) 2022-03-31
US20190383826A1 (en) 2019-12-19
EP3557254B1 (en) 2021-12-15
EP2593791B1 (en) 2016-11-23
PT2593791T (pt) 2017-02-01
CN103180734A (zh) 2013-06-26
EP2593792A1 (en) 2013-05-22
US20130183287A1 (en) 2013-07-18
PT2593792T (pt) 2020-01-29
ES3007288T3 (en) 2025-03-19
US20190383827A1 (en) 2019-12-19
US11162954B2 (en) 2021-11-02
WO2012007593A1 (en) 2012-01-19
PL2593792T3 (pl) 2020-05-18
EP2593791A1 (en) 2013-05-22
AU2011278244A1 (en) 2013-02-28
US9453065B2 (en) 2016-09-27
HUE031572T2 (en) 2017-07-28
US20190383828A1 (en) 2019-12-19
US12092646B2 (en) 2024-09-17
PL3557255T3 (pl) 2022-06-20
US20200025773A1 (en) 2020-01-23
US20190041400A1 (en) 2019-02-07
CA2805560C (en) 2019-10-29
DK2593792T3 (da) 2020-02-03
PL3557254T3 (pl) 2022-05-23
US20180067126A1 (en) 2018-03-08
BR112013001180B1 (pt) 2022-01-11
EP3557255B1 (en) 2021-11-17
EP3557257A1 (en) 2019-10-23
EP3557254A1 (en) 2019-10-23
JP6302248B2 (ja) 2018-03-28
WO2012007594A1 (en) 2012-01-19
EP4273549A1 (en) 2023-11-08
HRP20170201T1 (hr) 2017-04-07
US9689872B2 (en) 2017-06-27
JP2018027936A (ja) 2018-02-22
JP2021042209A (ja) 2021-03-18
DK2593791T3 (en) 2017-02-06
DK3557255T3 (da) 2022-01-24
CA2805560A1 (en) 2012-01-19
US20180100865A1 (en) 2018-04-12
ES2613532T3 (es) 2017-05-24
PL4273549T3 (pl) 2025-03-03
JP6859229B2 (ja) 2021-04-14
ES2905455T3 (es) 2022-04-08
JP2013536173A (ja) 2013-09-19
US11162953B2 (en) 2021-11-02
PT4273549T (pt) 2025-01-03
AU2011278244A8 (en) 2016-02-11
PT3557255T (pt) 2022-01-20
JP2023085340A (ja) 2023-06-20
EP3557255A1 (en) 2019-10-23
GB201014715D0 (en) 2010-10-20
HRP20220204T1 (hr) 2022-04-29
US20240103013A1 (en) 2024-03-28
DK4273549T3 (da) 2024-12-02
EP2593792B1 (en) 2019-11-13
ES2771479T3 (es) 2020-07-06
HRP20220326T1 (hr) 2022-05-13
US20170153245A1 (en) 2017-06-01
FI4273549T3 (fi) 2025-02-05
CN103180734B (zh) 2016-03-02
BR112013001180A2 (pt) 2016-05-31
US20190049463A1 (en) 2019-02-14
US20190383829A1 (en) 2019-12-19
US10078088B2 (en) 2018-09-18
EP3557256A1 (en) 2019-10-23
US20190383825A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
PL3557254T3 (pl) Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne GPCR i ich zastosowania
EP2655415A4 (en) THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
IL224523B (en) Mice producing binding proteins containing vl domains
PT2723764T (pt) Domínios de ligação dirigidos contra complexos gpcr:proteína g e suas utilizações derivadas
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
DE102011009669B8 (de) Architektur zur robusten Kraft- und Impedanzsteuerung von seriellen elastischen Stellgliedern
IL214643A0 (en) Specific binding proteins and uses thereof
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
LT2580240T (lt) S100a4 antikūnai ir jų terapinis panaudojimas
EP2478005A4 (en) CROSSLINKED CRYSTALS AND CRYSTALS OF PROTEIN A AND METHODS OF USE THEREOF
PL2441774T3 (pl) Peptydy zawierające motywy palców cynkowych i ich zastosowania
EP2534258A4 (en) KINAEDOMÄNEN WITH DOUBLE ACTIVITY AND USES THEREOF
PL2627192T3 (pl) Hydrolizaty białek zwierzęcych pochodzenia morskiego o właściwościach neuroprotekcyjnych
EP2324058A4 (en) BIOLOGICAL APPLICATION OF STEROID-BINDING DOMAINS
AU2010900887A0 (en) Protein domains and uses therefor-II
AU2010900571A0 (en) Protein domains and uses therefor
HK1190416A (en) Tri-variable domain binding proteins and uses thereof
GB201005972D0 (en) Solubilisation of membrane proteins